Clinical Trials on Recurrent Acral Lentiginous Melanoma

Total 197 results

Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Unresectable, Recurrent or Metastatic Melanoma | Untreated Mucosal or Acral Lentiginous Melanoma

China
Fred Hutchinson Cancer Center
Amazon.com Services LLC

Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditions

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Pfizer; Beth Israel Deaconess Medical Center

Completed

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United States
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Completed

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (NICAM)

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United Kingdom
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
Dana-Farber Cancer Institute
Novartis

Completed

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255)

Mucosal Melanoma | Acral/Lentiginous Melanoma | Chronically Sun Damaged Melanomas

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant Melanoma

United States
Chinese University of Hong Kong

Completed

Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Acral Lentiginous Melanoma

Hong Kong
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Neoadjuvant and Adjuvant Checkpoint Blockade

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Stage IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7 | Stage III Acral... and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC... and other conditions

United States
Georgetown University
Bristol-Myers Squibb; M.D. Anderson Cancer Center; University of Colorado, Denver and other collaborators

Terminated

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Mucosal Melanoma | Acral Lentiginous Melanoma

United States
National Cancer Institute (NCI)

Terminated

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant Melanoma

United States
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Intraocular Melanoma | Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Extraocular Extension Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Superficial... and other conditions

Canada
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Mucosal Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD Melanoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Acral Melanoma That Has Been Removed by Surgery

China
Yonsei University

Not yet recruiting

Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

Mucosal Melanoma | Acral Melanoma

Korea, Republic of
Peking University Cancer Hospital & Institute

Recruiting

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Acral Melanoma

China
Di Wu

Recruiting

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Acral Melanoma

China
Peking University Cancer Hospital & Institute

Unknown

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Melanoma
Peking University Cancer Hospital & Institute

Unknown

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Melanoma

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Metastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma

United States
Peking University Cancer Hospital & Institute
Kiang Wu Hospital

Unknown

Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma

Advanced Acral Malignant Melanoma

China
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
National Cancer Institute (NCI)

Completed

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Recurrent Melanoma | Stage IV Melanoma | Uveal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

Canada, United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Withdrawn

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Melanoma | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma
Peking University Cancer Hospital & Institute

Recruiting

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Melanoma | Temozolomide | Apatinib | Camrelizumab | Acral Melanoma | Neoadjuvant | Pathological Response

China
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage III Melanoma | Extraocular Extension Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Metastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...

United States, Canada, Ireland
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Incyte Corporation; University of Virginia

Completed

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma | Recurrent Uveal Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Metastatic Uveal Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Leptomeningeal Neoplasm | Metastatic Mucosal Melanoma | Central Nervous System Melanoma | Melanocytoma

United States
Gregory Daniels
Immunotherapy Foundation

Recruiting

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Metastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck Cancer

United States
Dana-Farber Cancer Institute
AstraZeneca

Withdrawn

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Recurrent Metastatic Melanoma

United States
Yale University
National Cancer Institute (NCI)

Completed

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

FDG-PET in Advanced Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Terminated

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
National Cancer Institute (NCI)

Terminated

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIc Melanoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Melanoma | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Terminated

Tanespimycin in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States

Clinical Trials on Recurrent Acral Lentiginous Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations